← FDA Drug Approvals (Drugs@FDA)

RELGAABI

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: SCIEGEN PHARMS · Approved 2016-02-18

Drug application

FDA Application #

ANDA204989

Application type

Abbreviated New Drug Application (Generic)

Brand name

RELGAABI

Generic name

GABAPENTIN

Active ingredients

GABAPENTIN

Dosage form

CAPSULE

Route

ORAL

Marketing status

Prescription

Sponsor

SCIEGEN PHARMS

Manufacturer

ScieGen Pharmaceuticals, Inc.

First approval

2016-02-18

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown